Morphotek Inc. will be moving forward with a phase 2 study of MORAb-009 monoclonal antibody in mesothelioma.
The study will be focused on MORAb-009 being used in addition to chemotherapy drugs that are currently the standard form of treatment for patients with mesothelioma. The objective is to show that MORAb-009 is an effective treatment based on progression-free survival in patients with locally advanced malignant pleural mesothelioma.
Beyond that, secondary objectives will be the safety and anti-tumor activity of the drug. Ideally MORAb-009 will block the function of mesothelin, a cell surface protein on mesothelioma, stopping further growth of any mesothelioma tumors.
Morphotek plans to enroll 86 patients in the study, with locally advanced malignant pleural mesothelioma, who have not been previously treated for the disease.